Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announced three-year follow-up results from the ovarian cancer cohort of its 400+ patie...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Na...
Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, announced that its Que Medical Inhalation Dev...
Samfara, a European life sciences investment firm, announced that it has completed the acquisition of Chr. Olesen Synthesis from Chr. Olesen and funds mana...
Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced tha...
Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions ...
Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepte...
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows suppor...
SkinHealth Systems (Nasdaq: SKIN), home to flagship brand Hydrafacial™, announced the European expansion of the SkinStylus® SteriLock® MicroS...
Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of Mironid’s lead LoAc® small molecule in healthy volunteers Dosing ...
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together l...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered d...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in dela...
© 2026 Biopharma Boardroom. All Rights Reserved.
